Overview

  • Dr. Shelton attended medical school at the University of Louisville in Kentucky. He was then a resident and Chief Resident at the Massachusetts Mental Health Center (now the Longwood Program), a teaching hospital of the Harvard Medical School in Boston, MA., followed by a research fellowship at the National Institutes of Mental Health Intramural Program in Washington, D.C. He joined the faculty of Vanderbilt University, where he became the James G. Blakemore Research Professor and Vice Chair for Clinical Research in the Department of Psychiatry. Dr. Shelton joined the faculty of the Department of Psychiatry and Behavioral Neurobiology at the University of Alabama at Birmingham in February 2012 as the Charles Byron Ireland Professor, Vice Chair for Research, and head of the Mood Disorders Program. Dr. Shelton has been an active physician-scientist and educator. He and his colleagues have had more than 120 funded research studies from the NIH, other Federal agencies, foundations, and industry. He has more than 350 publications, comprising original research reports, reviews, commentaries, and book chapters. Dr. Shelton’s research focuses on the development of new ways to treat and prevent depression and suicide.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2020 The impact of binge eating behavior on lithium- and quetiapine-associated changes in body weight, body mass index, and waist circumference during 6 months of treatment: Findings from the bipolar CHOICE study 2020
    2020 Erratum: Prevention of recurrence after recovery from a major depressive episode with antidepressant medication alone or in combination with cognitive behavioral therapy: phase 2 of a 2-phase randomized clinical trial (JAMA Psychiatry (2019) DOI: 10.1001/jamapsychiatry.2019.3900) 2020
    2020 Ketamine for acute suicidal ideation. An emergency department intervention: A randomized, double-blind, placebo-controlled, proof-of-concept trial 2020
    2020 Prevention of Recurrence after Recovery from a Major Depressive Episode with Antidepressant Medication Alone or in Combination with Cognitive Behavioral Therapy: Phase 2 of a 2-Phase Randomized Clinical Trial 2020
    2020 Real-world approach to managing dysgeusia following the use of esketamine nasal spray: A case report 2020
    2020 Effect of race on the relationship between child maltreatment and obesity in Whites and Blacks 2020
    2020 Improvement of sexual functioning during treatment of MDD with adjunctive pimavanserin: A secondary analysis 2020
    2019 Comparing sensitivity to change using the 6-item versus the 17-item Hamilton depression rating scale in the GUIDED randomized controlled trial 2019
    2019 Bipolar depression and suicidal ideation: Moderators and mediators of a complex relationship 2019
    2019 Analysis of Clinical Trial Exit Interview Data in Patients with Treatment-Resistant Depression 2019
    2019 Complex polypharmacy in bipolar disorder: Side effect burden, adherence, and response predictors 2019
    2019 Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing 2019
    2019 Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients with Treatment-Resistant Depression: A Randomized Clinical Trial 2019
    2019 Response to: Goldberg et al. and Severance et al. Letters to the Editor: The clinical significance of improving remission over standard of care – The reality of treatment resistant-based therapies 2019
    2019 Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: A randomized double-blind active-controlled study 2019
    2019 Patterns of changes in bipolar depressive symptoms revealed by trajectory analysis among 482 patients with bipolar disorder 2019
    2019 Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study 2019
    2019 Comorbid anxiety in bipolar CHOICE: Insights from the bipolar inventory of symptoms scale 2019
    2019 49 Combinatorial Pharmacogenomics to Guide Treatment Selection for Major Depressive Disorder: A Large, Blinded, Randomized Controlled Trial 2019
    2019 A phase 2, randomized, double-blind, placebo-controlled ST of adjunctive pimavanserin in patients with major depressive disorder and an inadequate response to therapy (CLARITY) 2019
    2019 Correlation between white blood cell count and mood-stabilising treatment response in two bipolar disorder trials 2019
    2019 Impact of pharmacogenomics on clinical outcomes for patients taking medications with gene-drug interactions in a randomized controlled trial 2019
    2019 Serotonin and Norepinephrine Reuptake Inhibitors 2019
    2018 Clinically relevant and simple immune system measure is related to symptom burden in bipolar disorder 2018
    2018 Decreased activation and subsyndromal manic symptoms predict lower remission rates in bipolar depression 2018
    2018 Treatment outcomes of acute bipolar depressive episode with psychosis 2018
    2018 Major Depressive Disorder Following Dermatomyositis: A Case Linking Depression with Inflammation 2018
    2018 Role of complex epigenetic switching in tumor necrosis factor-α upregulation in the prefrontal cortex of suicide subjects 2018
    2018 Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: A randomized clinical trial 2018
    2018 Corrigendum to bipolar mixed features – Results from the comparative effectiveness for bipolar disorder (Bipolar CHOICE) study [Journal of Affective Disorders 217 (2017) 183–189], (S0165032716323047), (10.1016/j.jad.2017.03.070)) 2018
    2018 Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD) 2018
    2018 Efficacy of ziprasidone augmentation of escitalopram for cognitive symptoms of major depressive disorder 2018
    2018 Interaction between early-life stress and FKBP5 gene variants in major depressive disorder and post-traumatic stress disorder: A systematic review and meta-analysis 2018
    2018 Sleep disturbance may impact treatment outcome in bipolar disorder: A preliminary investigation in the context of a large comparative effectiveness trial 2018
    2017 Brain structure, function, and neurochemistry in schizophrenia and bipolar disorder- A systematic review of the magnetic resonance neuroimaging literature 2017
    2017 Poor quality of life and functioning in bipolar disorder 2017
    2017 Trajectories of suicidal ideation over 6 months among 482 outpatients with bipolar disorder 2017
    2017 Gender-specific relationship between obesity and major depression 2017
    2017 Response to: Commentary: Sex differences in the peripheral immune system in patients with depression 2017
    2017 Clinical and genetic predictors of delayed remission after multiple levels of antidepressant treatment: Toward early identification of depressed individuals for advanced care options 2017
    2017 Bipolar mixed features – Results from the comparative effectiveness for bipolar disorder (Bipolar CHOICE) study 2017
    2017 Clinical correlates of acute bipolar depressive episode with psychosis 2017
    2017 Willingness of Mentally Ill Individuals to Sign Up for a Novel Proposal to Prevent Firearm Suicide 2017
    2017 Sex differences in the peripheral immune system in patients with depression 2017
    2017 DNA methylation and expression of stress related genes in PBMC of MDD patients with and without serious suicidal ideation 2017
    2017 A pilot trial of In vivo NRT sampling to increase medication adherence in community corrections smokers 2017
    2017 White blood cell count correlates with mood symptom severity and specific mood symptoms in bipolar disorder 2017
    2017 Ziprasidone augmentation of escitalopram for major depressive disorder: Cardiac, endocrine, metabolic, and motoric effects in a randomized, double-blind, placebo-controlled study 2017
    2017 Identification of MicroRNA-124-3p as a Putative Epigenetic Signature of Major Depressive Disorder 2017
    2017 Nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol do not affect 6-month mood-stabilizing treatment outcome among 482 patients with bipolar disorder 2017
    2016 Depression, Antidepressants, and Weight Gain in Children 2016
    2016 Dimensions of schizophrenia and their time course of response to a second generation antipsychotic olanzapine—A clinical study 2016
    2016 Psilocybin and palliative end-of-life care 2016
    2016 Tracking medication changes to assess outcomes in comparative effectiveness research: A bipolar CHOICE study 2016
    2016 Ziprasidone augmentation for anxious depression 2016
    2016 A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression 2016
    2016 Specific pharmacological effects of paroxetine comprise psychological but not somatic symptoms of depression 2016
    2016 Notice of Retraction and Replacement. Hollon et al. Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder: A randomized clinical trial. JAMA Psychiatry. 2014;71(10):1157-1164 2016
    2016 An altered peripheral IL6 response in major depressive disorder 2016
    2016 Are placebo-controlled trials of depression safe? 2016
    2016 Long-Term Efficacy, Safety, and Tolerability of l-Methylfolate Calcium 15 mg as Adjunctive Therapy With Selective Serotonin Reuptake Inhibitors: A 12-Month, Open-Label Study Following a Placebo-Controlled Acute Study 2016
    2016 Impact of Major Depressive Disorder on Prediabetes by Impairing Insulin Sensitivity. 2016
    2016 The course of illness after initial diagnosis of major depression 2016
    2016 A tool to predict suicidal ideation and behavior in bipolar disorder: The Concise Health Risk Tracking Self-Report 2016
    2016 Molecular analyses of circadian gene variants reveal sex-dependent links between depression and clocks 2016
    2016 A placebo-controlled crossover study of iloperidone augmentation for residual anger and irritability in major depressive disorder. 2016
    2016 Baseline disability and poor functioning in Bipolar disorder predict worse outcomes: Results from the Bipolar CHOICE study 2016
    2016 Bipolar CHOICE (clinical health outcomes initiative in comparative effectiveness): A pragmatic 6-month trial of lithium versus quetiapine for Bipolar disorder 2016
    2016 Obesity, but not metabolic syndrome, negatively affects outcome in bipolar disorder 2016
    2015 Association of obesity and inflammatory marker levels on treatment outcome: Results from a double-blind, randomized study of adjunctive l-methylfolate calcium in patients with MDD who are inadequate responders to SSRIs 2015
    2015 Ziprasidone augmentation of escitalopram for major depressive disorder: Efficacy results from a randomized, Double-Blind, Placebo-Controlled Study 2015
    2015 The pro-inflammatory profile of depressed patients is (partly) related to obesity 2015
    2015 Childhood maltreatment increases the risk for visceral obesity 2015
    2015 Psychotherapy use in bipolar disorder: Association with functioning and illness severity 2015
    2015 Medical burden in bipolar disorder: Findings from the Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder study (Bipolar CHOICE) 2015
    2015 Coordinated messenger RNA/microRNA changes in fibroblasts of patients with major depression 2015
    2015 Assessment of the Efficacy and Safety of BMS-820836 in Patients with Treatment-Resistant Major Depression: Results from 2 Randomized, Double-Blind Studies 2015
    2015 Complexity of illness and adjunctive benzodiazepine use in outpatients with bipolar i or II disorder results from the bipolar CHOICE study 2015
    2015 Fibroblasts from patients with major depressive disorder show distinct transcriptional response to metabolic stressors 2015
    2015 Gains in employment status following antidepressant medication or cognitive therapy for depression 2015
    2015 MDDScore: Confirmation of a blood test to aid in the diagnosis of major depressive disorder 2015
    2015 Reply to commentary by rothschild: "A blood test for depression?" 2015
    2015 What are the comparative benefits and harms of augmentation treatments in major depression? 2015
    2014 Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder a randomized clinical trial 2014
    2014 Erratum: "Effect of adjunctive benzodiazepines on clinical outcomes in lithium- or quetiapine-treated outpatients with bipolar i or II disorder: Results from the bipolar CHOICE trial" [Journal of Affective Disorders (2014) 161 (30-35)] 2014
    2014 Posttraumatic stress disorder after high-dose-rate brachytherapy for cervical cancer: In regard to Kirchheiner et al 2014
    2014 Effect of adjunctive benzodiazepines on clinical outcomes in lithium- or quetiapine-treated outpatients with bipolar i or II disorder: Results from the Bipolar CHOICE trial 2014
    2014 Antidepressants and suicide attempts in children 2014
    2014 Clinical and health outcomes initiative in comparative effectiveness for bipolar disorder (Bipolar CHOICE): A pragmatic trial of complex treatment for a complex disorder 2014
    2014 The effect of regulatory advisories on maternal antidepressant prescribing, 1995-2007: An interrupted time series study of 228,876 pregnancies 2014
    2014 Metabolic stress-induced microRNA and mRNA expression profiles of human fibroblasts 2014
    2014 BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine 2014
    2014 Early life trauma and directional brain connectivity within major depression 2014
    2014 Rapid Follow-Up for Patients After Psychiatric Crisis 2014
    2013 Association of exercise with quality of life and mood symptoms in a comparative effectiveness study of bipolar disorder 2013
    2013 Assessing effects of L-methylfolate in depression management: Results of a real-world patient experience trial 2013
    2013 Identifying suicidal behavior among adolescents using administrative claims data 2013
    2013 Increasing use of atypical antipsychotics and anticonvulsants during pregnancy 2013
    2013 Erratum: Maternal antidepressant use and adverse outcomes: A cohort study of 228,876 pregnancies (American Journal of Obstetrics and Gynecology (2012) 207 49 (e1-9)) 2013
    2013 Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: A Pilot and Replication Study 2013
    2013 Convergence and divergence in the delivery of cognitive therapy intwo randomized clinical trials 2013
    2013 Differential change in specific depressive symptoms during antidepressant medication or cognitive therapy 2013
    2013 Mitochondrial modulators for bipolar disorder: A pathophysiologically informed paradigm for new drug development 2013
    2013 Reliability and validity of the Symptoms of Depression Questionnaire (SDQ) 2013
    2013 Treatment resistant depression: Strategies for primary care topical collection on psychiatry in primary care 2013
    2012 L-methylfolate as adjunctive therapy for SSRI-resistant major depression: Results of two randomized, double-blind,,parallel-sequential trials 2012
    2012 Does concomitant use of NSAIDs reduce the effectiveness of antidepressants? 2012
    2012 Predictors of patient cognitive therapy skills and symptom change in two randomized clinical trials: The role of therapist adherence and the therapeutic alliance 2012
    2012 Depression in patients with head and neck cancer and a functional genetic polymorphism of the serotonin transporter gene 2012
    2012 A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder 2012
    2012 Effort-based decision-making in major depressive disorder: A translational model of motivational anhedonia 2012
    2012 Maternal antidepressant use and adverse outcomes: A cohort study of 228,876 pregnancies 2012
    2012 Oxidative stress and glutathione response in tissue cultures from persons with major depression 2012
    2012 Review of pharmacological treatment in mood disorders and future directions for drug development 2012
    2011 A Randomized open comparison of long-acting injectable risperidone and treatment as usual for prevention of relapse, rehospitalization, and urgent care referral in community-treated patients with rapid cycling bipolar disorder 2011
    2011 Functional biomarkers of depression: Diagnosis, treatment, and pathophysiology 2011
    2011 Inflammation in depression: Is adiposity a cause? 2011
    2011 Agomelatine for the treatment of major depressive disorder 2011
    2011 Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: A CO-MED report 2011
    2011 Sustained amygdala response to both novel and newly familiar faces characterizes inhibited temperament 2011
    2011 Suicidal behavior differs among early and late adolescents treated with antidepressant agents 2011
    2011 Effects of orally disintegrating vs regular olanzapine tablets on body weight, eating behavior, glycemic and lipid indices, and gastrointestinal hormones: A randomized, open comparison in outpatients with bipolar depression 2011
    2011 Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression 2011
    2011 Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and long-term outcomes of a single-blind randomized study 2011
    2011 Using moderator-based algorithms and electronic medical records to achieve optimal outcomes in depression. 2011
    2011 Two aspects of the therapeutic alliance: Differential relations with depressive symptom change 2011
    2011 Challenges and algorithm-guided treatment in major depressive disorder. 2011
    2011 Crisis of confidence: antidepressant risk versus benefit. 2011
    2011 The relationship between adverse events during selective serotonin reuptake inhibitor treatment for major depressive disorder and nonremission in the suicide assessment methodology study 2011
    2011 A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression 2011
    2011 Childhood trauma history differentiates amygdala response to sad faces within MDD 2011
    2011 Evidence for the use of l-methylfolate combined with antidepressants in MDD. 2011
    2011 Moderators of antidepressant response in major depression. 2011
    2011 Performance improvement CME: algorithms and EMRs in depression. 2011
    2011 Using algorithms and computerized decision support systems to treat major depression. 2011
    2010 Biological activities of 7-dehydrocholesterol-derived oxysterols: Implications for Smith-Lemli-Opitz syndrome 2010
    2010 Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release 2010
    2010 Risperidone long-acting injectable (Risperdal Consta®) for maintenance treatment in patients with bipolar disorder 2010
    2010 Can pharmacotherapists be too supportive? A process study of active medication and placebo in the treatment of depression 2010
    2010 Efficacy, safety and tolerability of Symbyax® for acute-phase management of treatment-resistant depression 2010
    2010 Depressive realism and clinical depression 2010
    2010 Olanzapine monotherapy for acute depression in patients with bipolar I or II disorder: Results of an 8-week open label trial 2010
    2010 Therapeutic options for treatment-resistant depression 2010
    2010 Antidepressant drug effects and depression severity: A patient-level meta-analysis 2010
    2010 Acute bipolar depression: A review of the use of olanzapine/fluoxetine 2010
    2010 Converting from brand-name to generic clozapine: A review of effectiveness and tolerability data 2010
    2010 Eating ourselves to death (and despair): The contribution of adiposity and inflammation to depression 2010
    2009 St John's wort (Hypericum perforatum) in major depression 2009
    2009 Long-term management of depression: Tips for adjusting the treatment plan as the patient's needs change 2009
    2009 Amygdala temporal dynamics: Temperamental differences in the timing of amygdala response to familiar and novel faces 2009
    2009 Effectiveness study of venlafaxine-XR combined with aripiprazole for chronic or recurrent major depressive disorder 2009
    2009 Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study 2009
    2009 Personality change during depression treatment: A placebo-controlled trial 2009
    2009 Olanzapine and fluoxetine combination therapy for treatment-resistant depression: Review of efficacy, safety, and study design issues 2009
    2009 Protein kinases A and C in post-mortem prefrontal cortex from persons with major depression and normal controls 2009
    2009 Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: Review of efficacy and safety data 2009
    2009 Prediction of Response to Medication and Cognitive Therapy in the Treatment of Moderate to Severe Depression 2009
    2009 Symbyax ® (olanzapine and fluoxetine HCl) for the acute treatment of treatment-resistant depression 2009
    2009 Treatment-resistant depression: Understanding its nature and the burden of care 2009
    2009 Early adverse events, HPA activity and rostral anterior cingulate volume in MDD 2009
    2009 Elevated 5-HT 2A receptors in postmortem prefrontal cortex in major depression is associated with reduced activity of protein kinase A 2009
    2009 Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine 2009
    2009 Factors associated with concomitant psychotropic drug use in the treatment of major depression: A STAR*D report 2009
    2009 Psychiatric profile and attention deficits in postural tachycardia syndrome 2009
    2009 The role of L-methylfolate in depressive disorders: commentary. 2009
    2009 The role of residual symptoms in nonadherence to treatment. 2009
    2008 Adjunctive use of modafinil in bipolar patients: Just another stimulant or not? 2008
    2008 Use of atypical antipsychotics for treatment-resistant major depressive disorder 2008
    2008 Sequence of improvement in depressive symptoms across cognitive therapy and pharmacotherapy 2008
    2008 Multivariate permutation analysis associates multiple polymorphisms with subphenotypes of major depression 2008
    2008 Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder 2008
    2008 Antidepressant medications v. cognitive therapy in people with depression with or without personality disorder 2008
    2008 The history and current state of antidepressant clinical trial design: A call to action for proof-of-concept studies 2008
    2007 The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the Acute and Continuation Phases 2007
    2007 Are Antidepressant Drugs That Combine Serotonergic and Noradrenergic Mechanisms of Action More Effective Than the Selective Serotonin Reuptake Inhibitors in Treating Major Depressive Disorder? A Meta-analysis of Studies of Newer Agents 2007
    2007 Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression 2007
    2007 Augmentation strategies to increase antidepressant efficacy 2007
    2007 Dr. Shelton replies [4] 2007
    2007 The Relation of Patients' Treatment Preferences to Outcome in a Randomized Clinical Trial 2007
    2007 The neurobiology of treatment-resistant depression 2007
    2007 Changes in patients' beliefs about the causes of their depression following successful treatment 2007
    2007 Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression 2007
    2007 The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: Outcomes from the 2-year and combined maintenance phases 2007
    2007 Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: A randomized, open-label, pilot study 2007
    2007 Issues related to adherence in the treatment of depression 2007
    2007 Sudden Gains in Cognitive Therapy of Depression and Depression Relapse/Recurrence 2007
    2007 Progressive Resistance to a Selective Serotonin Reuptake Inhibitor but Not to Cognitive Therapy in the Treatment of Major Depression 2007
    2007 Comparison of quality of life measures in a depressed population 2007
    2007 The Molecular Neurobiology of Depression 2007
    2007 A randomized, double-blind, crossover trial of modafinil on mood 2007
    2007 Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer 2007
    2007 Polymorphisms in the Regulatory Region of the Human Serotonin 5-HT2A Receptor Gene (HTR2A) Influence Gene Expression 2007
    2007 Are depressed outpatients with and without a family history of substance use disorder different? A baseline analysis of the STAR*D cohort 2007
    2007 Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: A meta-analysis 2007
    2007 Case Studies in Bipolar Depression: Best Practices for the Outpatient 2007
    2007 Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT study 2007
    2006 Use of treatment algorithms for depression 2006
    2006 Praise for a critical perspective 2006
    2006 The return of fixed combinations in psychiatry: Fluoxetine and olanzapine combination 2006
    2006 Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: A randomized comparison of standard- and higher-dosing strategies 2006
    2006 Antidepressant discontinuation syndrome: Consensus panel recommendations for clinical management and additional research 2006
    2006 The nature of the discontinuation syndrome associated with antidepressant drugs 2006
    2006 Norepinephrine transporter-deficient mice respond to anxiety producing and fearful environments with bradycardia and hypotension 2006
    2006 Management of major depressive disorder following failure of first antidepressant treatment 2006
    2006 Presenting characteristics of depressed outpatients as a function of recurrence: Preliminary findings from the STAR*D clinical trial 2006
    2006 A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder 2006
    2006 Detection of an mRNA polymorphism by differential display. 2006
    2006 Olanzapine/fluoxetine combination for bipolar depression 2006
    2005 Sequence variation in the human dopamine transporter gene in children with attention deficit hyperactivity disorder 2005
    2005 Human serotonin transporter variants display altered sensitivity to protein kinase G and p38 mitogen-activated protein kinase 2005
    2005 Comorbid psychiatric disorders in depressed outpatients: Demographic and clinical features 2005
    2005 Cognitive therapy vs medications in the treatment of moderate to severe depression 2005
    2005 Prevention of relapse following cognitive therapy vs medications in moderate to severe depression 2005
    2005 Signal transduction abnormalities in melancholic depression 2005
    2005 Do venlafaxine XR and paroxetine equally influence negative and positive affect? 2005
    2005 Olanzapine/fluoxetine combination for treatment-resistant depression: A controlled study of SSRI and nortriptyline resistance 2005
    2005 Treatment of depression in adolescents with cognitive behavior therapy and medications: A commentary on the TADS project 2005
    2004 Risperidone and paroxetine given singly and in combination for bipolar depression 2004
    2004 The dual-action hypothesis: Does pharmacology matter? 2004
    2004 Decreased serotonin 5-HT2A receptor-stimulated phosphoinositide signalling in fibroblasts from melancholic deppresed patients 2004
    2004 The effectiveness of St. John's wort in major depressive disorder: A naturalistic phase 2 follow-up in which nonresponders were provided alternate medication 2004
    2004 Early- and late-onset startle modulation in unipolar depression 2004
    2004 Assessing the effects of bupropion SR on mood dimensions of depression 2004
    2004 Differential Expression of Pentraxin 3 in Fibroblasts from Patients with Major Depression 2004
    2003 The combination of olanzapine and fluoxetine in mood disorders 2003
    2003 The combination of olanzapine and fluoxetine in mood disorders. 2003
    2003 The use of antidepressants in novel combination therapies 2003
    2003 Treating bipolar depression 2003
    2002 St John's wort for the treatment of depression 2002
    2002 Noradrenergic antidepressants: Does chronic treatment increase or decrease nuclear CREB-P? 2002
    2002 Mechanism of action of antidepressants. 2002
    2001 St John's wort was no better than placebo for reducing depression scores 2001
    2001 Steps following attainment of remission: Discontinuation of antidepressant therapy 2001
    2001 Antidepressant therapy: New targets for drug development 2001
    2001 Can recovery from depression be achieved? 2001
    2001 Detection of an mRNA polymorphism by Differential Display 2001
    2001 Cross-talk between PKA and PKC in human fibroblasts: What are the pharmacotherapeutic implications? 2001
    2001 Mechanisms of action in the treatment of anxiety 2001
    2001 St John's wort and major depression [1] 2001
    2001 St john's wort and major depression. 2001
    2001 Effectiveness of St John's wort in major depression: A randomized controlled trial 2001
    2001 A novel augmentation strategy for treating resistant major depression 2001
    2001 Do Dual-Action Neurotransmitter Agents Offer an Advantage in Psychiatric Treatment? 2001
    2001 Introduction: Remission of anxiety-related disorders 2001
    2001 Serum thyrotropin concentrations and bioactivity during sleep deprivation in depression 2001
    2001 Treatment guidelines for major depressive disorder 2001
    2000 Chronic depression: Now, a treatable condition 2000
    2000 Human fibroblasts as a relevant model to study signal transduction in affective disorders 2000
    2000 Cellular mechanisms in the vulnerability to depression and response to antidepressants 2000
    2000 Intracellular mechanisms of antidepressant drug action 2000
    1999 The reliability and validity of a measure of self-understanding of interpersonal patterns 1999
    1999 Mood-stabilizing drugs in depression 1999
    1999 Treatment options for refractory depression 1999
    1999 Cyclic AMP-dependent protein kinase in subtypes of major depression and normal volunteers 1999
    1998 Update on the management of bipolar illness 1998
    1997 Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: Psychosocial outcomes 1997
    1997 The undertreatment of dysthymia 1997
    1996 cAMP-dependent protein kinase activity in major depression 1996
    1996 β-Adrenoceptor-linked protein kinase A (PKA) activity in human fibroblasts from normal subjects and from patients with major depression 1996
    1995 Effects of a Safe Person on Induced Distress Following a Biological Challenge in Panic Disorder With Agoraphobia 1995
    1994 The role of sertraline in the management of depression 1994
    1993 Cognitive Therapy for Depression: Conceptual Issues and Clinical Efficacy 1993
    1993 The effects of antidepressants on the thyroid axis in depression 1993
    1993 Alprazolam in panic disorder: A retrospective analysis 1993
    1993 Cerebrospinal fluid norepinephrine concentrations and dynamics in depressed patients and normal volunteers 1993
    1993 Pharmacotherapy of panic disorder 1993
    1993 Sleep deprivation accelerates the response to nortriptyline 1993
    1993 The effects of race and comorbidity on clinical diagnosis in patients with psychosis 1993
    1992 Psychiatric phenomenology in Cushings's disease 1992
    1991 Cognitive Therapy and Pharmacotherapy for Depression 1991
    1991 Biological and psychological aspects of depression 1991
    1991 The nucleus basalis of Meynert, senile plaques, and intellectual impairment in schizophrenia 1991
    1990 Diagnosis and management of panic disorder 1990
    1988 Cerebral structural pathology in schizophrenia: Evidence for a selective prefrontal cortical defect 1988
    1987 Diltiazem or verapamil prevents haloperidol-induced apomorphine supersensitivity in mice 1987
    1987 Induction of seizures in mice by intracerebroventricular administration of the calcium channel agonist BAY k 8644 1987
    1987 A relationship between anatomical and physiological brain pathology in schizophrenia: Lateral cerebral ventricular size predicts cortical blood flow 1987
    1987 Effect of chronic nicotine administration on monoamine and monoamine metabolite concentrations in rat brain 1987
    1986 A negative, double-blind, placebo-controlled, clinical trial of verapamil in chronic schizophrenia 1986
    1986 Consent and liability with neuroleptics: The problem of tardive dyskinesia 1986
    1985 Metabolism of carbidopa to alphamethyldopamine and alphamethylnorepinephrine in rats 1985
    1985 Nitrendipine-sensitive Ca2+ channels in mouse brain: Evidence for down-regulation of recognition sites after long-term treatment with nifedipine or verapamil 1985

    Chapter

    Year Title Altmetric
    2016 Anxiety disorders.  145-168. 2016
    2015 microRNAs as novel players in depression pathogenesis and in the mechanisms of action of fluoxetine and other antidepressants.  147-166. 2015
    2008 Anxiety disorders.  133-159. 2008

    Research Overview

  • Depression. Suicide. Bipolar disorder. Experimental therapeutics. Biomarker identification.
  • Principal Investigator On

  • Private Grant  awarded by OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC 2018 - 2022
  • Private Grant  awarded by ACADIA PHARMACEUTICALS, INC. 2020 - 2022
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2016 - 2022
  • Private Grant  awarded by ACADIA PHARMACEUTICALS, INC. 2019 - 2021
  • Private Grant  awarded by Janssen 2016 - 2021
  • Private Grant  awarded by Janssen 2016 - 2021
  • Private Grant  awarded by NEURORX 2020 - 2021
  • Private Grant  awarded by NEURORX 2020 - 2021
  • Augmentation Versus Switch: Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders with Treatment Resistant Depression (ASCERTAIN-TRD)  awarded by PATIENT CENTERED OUTCOMES RESEARCH INSTITUTE 2017 - 2020
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION - NEW 2019 - 2020
  • MicroRNA Mediators of Early Life Stress Vulnerability and Resilience  awarded by National Institute of Mental Health/NIH/DHHS 2017 - 2020
  • Private Grant  awarded by ACADIA PHARMACEUTICALS, INC. 2017 - 2019
  • Private Grant  awarded by ALLERGAN, INC. 2018 - 2019
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2016 - 2019
  • Private Grant  awarded by ALLERGAN, INC. 2019
  • Private Grant  awarded by INTRA-CELLULAR THERAPIES INC. 2018 - 2019
  • Private Grant  awarded by ALLERGAN SALES, LLC 2017 - 2019
  • Private Grant  awarded by ALLERGAN SALES, LLC 2017 - 2019
  • Private Grant  awarded by NAVITOR PHARMACEUTICALS INC. 2019
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2017 - 2019
  • Private Grant  awarded by NEURORX 2017 - 2019
  • Private Grant  awarded by ALLERGAN SALES, LLC 2017 - 2019
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2015 - 2018
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2015 - 2018
  • A Placebo-Controlled, Crossover Study of Fanapt® (iloperidone) Augmentation of SSRIs for Residual Anger and Irritability in Major Depressive Disorder  awarded by MASSACHUSETTS GENERAL HOSPITAL 2013 - 2018
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2015 - 2018
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2015 - 2018
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2017 - 2018
  • Private Grant  awarded by ALLERGAN, INC. 2016 - 2018
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2015 - 2018
  • Private Grant  awarded by ALKERMES, INC. 2014 - 2017
  • Private Grant  awarded by FOREST LABORATORIES, INC. 2014 - 2017
  • Private Grant  awarded by NAUREX, INC. 2012 - 2017
  • Private Grant  awarded by NAUREX, INC. 2014 - 2017
  • Private Grant  awarded by ALKERMES, INC. 2014 - 2017
  • Private Grant  awarded by TAL MEDICAL 2013 - 2017
  • Private Grant  awarded by GENOMIND 2016
  • Rapidly-Acting Treatments for Treatment-Resistance Depression  awarded by MASSACHUSETTS GENERAL HOSPITAL 2012 - 2016
  • Private Grant  awarded by OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC 2012 - 2016
  • Double-Blind, Placebo-Controlled, Proof-of-Concept (POC) Trial of CERC-501, a Kappa-Selective Opioid Receptor Antagonist, Augmentation of Antidepressant Therapy in Treatment-Resistant Depression (TRD)  awarded by MASSACHUSETTS GENERAL HOSPITAL 2015 - 2016
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2014 - 2016
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2014 - 2015
  • Private Grant  awarded by ASSUREX HEALTH INC. 2014 - 2015
  • Private Grant  awarded by AVANIR PHARMACEUTICALS, INC. 2014 - 2015
  • Private Grant  awarded by TAKEDA GLOBAL RESEARCH & DEVELOPMENT CENTER 2012 - 2015
  • Private Grant  awarded by TAKEDA GLOBAL RESEARCH & DEVELOPMENT CENTER 2012 - 2015
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2012 - 2015
  • Private Grant  awarded by OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC 2013 - 2015
  • Private Grant  awarded by PAMLAB LLC 2014 - 2015
  • Assay of Inflammatory Cytokines, High Sensitivity C-Reactive Protein, Leptin, and Insulin in Plasma Samples of Outpatient Participants in L-Methylfolate (Deplin®) TRD-I and TRD-II Trials  awarded by MASSACHUSETTS GENERAL HOSPITAL 2013 - 2015
  • Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation  awarded by American Foundation for Suicide Prevention 2012 - 2014
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2014
  • Private Grant  awarded by CERECOR, INC. 2013 - 2014
  • Private Grant  awarded by Janssen 2013 - 2014
  • Private Grant  awarded by Elan 2012 - 2014
  • 2/2- Ziprasidone Augmentation of SSRIs for Treatment-Resistant Depression  awarded by National Institute of Mental Health/NIH/DHHS 2012 - 2014
  • Private Grant  awarded by Janssen 2013 - 2014
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2012 - 2013
  • Comparative Effectiveness of a Second Generation Antipsychotic Mood Stabilizer and a Classic Mood Stabilizer for Bipolar Disorder  awarded by MASSACHUSETTS GENERAL HOSPITAL 2012 - 2013
  • Statistical Methods for Comparative Treatment Effectiveness Using Claims Data  awarded by VANDERBILT UNIVERSITY MEDICAL CENTER 2012 - 2013
  • Investigator On

  • Epitranscriptomic Mapping of Novel N6-Adenosine-based RNA Methylation in MDD Brain  awarded by National Institute of Mental Health/NIH/DHHS 2019 - 2024
  • Balanced Placebo Design with Varenicline: Pharmacological and Expectancy Effects on Medication Adherence  awarded by National Institute on Drug Abuse/NIH/DHHS 2018 - 2021
  • A Sleep and Media Intervention to Improve Adolescents Weight and Risk of Type 2 Diabetes  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2016 - 2021
  • Plasma Exosomal MicroRNAs as Promising Novel Biomarkers for Suicidality and Treatment Outcome  awarded by National Institute of Mental Health/NIH/DHHS 2015 - 2021
  • Structural and Neurometabolic White Matter Integrity in the Deficit Syndrome  awarded by National Institute of Mental Health/NIH/DHHS 2015 - 2020
  • NRT Sampling and Selection to Increase Medication Adherence  awarded by National Institute on Drug Abuse/NIH/DHHS 2017 - 2020
  • Identification for Predictors of Future Diabetes - Impacts of Stress and Depression  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2015 - 2019
  • Plasma MicroRNAs as Biomarker for Suicidality and Treatment Outcome  awarded by American Foundation for Suicide Prevention 2015 - 2018
  • Private Grant  awarded by ASSUREX HEALTH INC. 2016 - 2018
  • Private Grant  awarded by ASSUREX HEALTH INC. 2016
  • [18F] FPEB Studies of the mGluR5 Receptor and Methamphetamine Abuse  awarded by National Institute on Drug Abuse/NIH/DHHS 2014 - 2016
  • Glucose Metabolism and Insulin Sensitivity in Depressed Patients following Early Life Stress  awarded by Brain and Behavior Research Foundation 2014 - 2016
  • Training Interventions and Genetics of Exercise Response (TIGER)  awarded by University of Texas at Austin 2013 - 2015
  • Private Grant  awarded by INNOPHARMA, INC. 2013 - 2014
  • Education And Training

  • Doctor of Medicine, University of Louisville 1979
  • Bachelor of Science or Mathematics, East Tennessee State University 1975
  • University of Louisville Hospital, Internship 1980
  • Harvard Medical School, Residency 1983
  • National Institute of Mental Health & Neuroscience, Postdoctoral Fellowship 1985
  • Full Name

  • Richard Shelton